Use of corticosteroids has been most frequently associated with bone loss, but heparin and methotrexate, when used in relatively high doses, have also been linked to the development of osteoporosis. Clinical features of bone loss associated with these agents, possible pathophysiologic mechanisms, and strategies for avoiding this complication are reviewed.